Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201126 | 0.93 | FYN (0.71) | FYNHIF1ASLC2A4CYP3A4CCNT1 | |
| SCHEMBL4191787 | 0.93 | FYN (0.71) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4146617 | 0.93 | FYN (0.64) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4185311 | 0.92 | FYN (0.63) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4191627 | 0.91 | FYN (0.65) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4155633 | 0.91 | FYN (0.62) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4199084 | 0.91 | FYN (0.61) | FYNHIF1ASLC2A4CYP3A4CYP1A2 | |
| SCHEMBL4138960 | 0.90 | FYN (0.60) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4187608 | 0.90 | FYN (0.60) | FYNHIF1ASLC2A4CYP3A4PKM | |
| SCHEMBL4187374 | 0.89 | FYN (0.67) | FYNCYP3A4CYP1A2ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | FYN 114/4885HIF1A 2872/4885SLC2A4 3753/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | FYN 3292/4885HIF1A 4493/4885SLC2A4 4744/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | FYN 3292/4885HIF1A 4493/4885SLC2A4 4744/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | FYN 3292/4885HIF1A 4493/4885SLC2A4 4744/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | FYN 173/4885HIF1A 4775/4885SLC2A4 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.